Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $10.87 billion. The enterprise value is $9.86 billion.
| Market Cap | 10.87B |
| Enterprise Value | 9.86B |
Important Dates
The next estimated earnings date is Monday, August 3, 2026, before market open.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 29.48 million shares outstanding. The number of shares has increased by 0.75% in one year.
| Current Share Class | 29.48M |
| Shares Outstanding | 29.48M |
| Shares Change (YoY) | +0.75% |
| Shares Change (QoQ) | +0.85% |
| Owned by Insiders (%) | 10.25% |
| Owned by Institutions (%) | 88.40% |
| Float | 23.42M |
Valuation Ratios
The trailing PE ratio is 49.36 and the forward PE ratio is 42.92. Krystal Biotech's PEG ratio is 0.68.
| PE Ratio | 49.36 |
| Forward PE | 42.92 |
| PS Ratio | 26.04 |
| Forward PS | n/a |
| PB Ratio | 8.50 |
| P/TBV Ratio | 8.51 |
| P/FCF Ratio | 45.78 |
| P/OCF Ratio | 43.42 |
| PEG Ratio | 0.68 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 54.63, with an EV/FCF ratio of 41.53.
| EV / Earnings | 43.81 |
| EV / Sales | 23.62 |
| EV / EBITDA | 54.63 |
| EV / EBIT | 55.16 |
| EV / FCF | 41.53 |
Financial Position
The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.46 |
| Quick Ratio | 8.82 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | 0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 19.90% and return on invested capital (ROIC) is 41.40%.
| Return on Equity (ROE) | 19.90% |
| Return on Assets (ROA) | 9.04% |
| Return on Invested Capital (ROIC) | 41.40% |
| Return on Capital Employed (ROCE) | 13.86% |
| Weighted Average Cost of Capital (WACC) | 6.98% |
| Revenue Per Employee | $1.41M |
| Profits Per Employee | $762,814 |
| Employee Count | 295 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.67 |
Taxes
| Income Tax | -17.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +157.62% in the last 52 weeks. The beta is 0.50, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +157.62% |
| 50-Day Moving Average | 315.00 |
| 200-Day Moving Average | 256.08 |
| Relative Strength Index (RSI) | 68.28 |
| Average Volume (20 Days) | 389,976 |
Short Selling Information
The latest short interest is 3.14 million, so 10.65% of the outstanding shares have been sold short.
| Short Interest | 3.14M |
| Short Previous Month | 3.15M |
| Short % of Shares Out | 10.65% |
| Short % of Float | 13.40% |
| Short Ratio (days to cover) | 12.47 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $417.30 million and earned $225.03 million in profits. Earnings per share was $7.47.
| Revenue | 417.30M |
| Gross Profit | 392.96M |
| Operating Income | 178.73M |
| Pretax Income | 207.32M |
| Net Income | 225.03M |
| EBITDA | 180.47M |
| EBIT | 178.73M |
| Earnings Per Share (EPS) | $7.47 |
Balance Sheet
The company has $823.41 million in cash and $9.11 million in debt, with a net cash position of $1.01 billion or $34.19 per share.
| Cash & Cash Equivalents | 823.41M |
| Total Debt | 9.11M |
| Net Cash | 1.01B |
| Net Cash Per Share | $34.19 |
| Equity (Book Value) | 1.28B |
| Book Value Per Share | 43.37 |
| Working Capital | 911.94M |
Cash Flow
In the last 12 months, operating cash flow was $250.28 million and capital expenditures -$12.90 million, giving a free cash flow of $237.38 million.
| Operating Cash Flow | 250.28M |
| Capital Expenditures | -12.90M |
| Depreciation & Amortization | 1.74M |
| Net Borrowing | n/a |
| Free Cash Flow | 237.38M |
| FCF Per Share | $8.05 |
Margins
Gross margin is 94.17%, with operating and profit margins of 42.83% and 53.92%.
| Gross Margin | 94.17% |
| Operating Margin | 42.83% |
| Pretax Margin | 49.68% |
| Profit Margin | 53.92% |
| EBITDA Margin | 43.25% |
| EBIT Margin | 42.83% |
| FCF Margin | 56.88% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.75% |
| Shareholder Yield | -0.75% |
| Earnings Yield | 2.07% |
| FCF Yield | 2.18% |
Analyst Forecast
The average price target for Krystal Biotech is $349.78, which is -5.11% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $349.78 |
| Price Target Difference | -5.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 31.18% |
| EPS Growth Forecast (3Y) | 26.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 29.48 and a Piotroski F-Score of 5.
| Altman Z-Score | 29.48 |
| Piotroski F-Score | 5 |